GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Initiator Pharma AS (OSTO:INIT) » Definitions » EV-to-FCF

Initiator Pharma AS (OSTO:INIT) EV-to-FCF : -17.36 (As of Apr. 07, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Initiator Pharma AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Initiator Pharma AS's Enterprise Value is kr317.56 Mil. Initiator Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-18.29 Mil. Therefore, Initiator Pharma AS's EV-to-FCF for today is -17.36.

The historical rank and industry rank for Initiator Pharma AS's EV-to-FCF or its related term are showing as below:

OSTO:INIT' s EV-to-FCF Range Over the Past 10 Years
Min: -17.36   Med: 0   Max: 0
Current: -17.36

OSTO:INIT's EV-to-FCF is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 2.335 vs OSTO:INIT: -17.36

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-07), Initiator Pharma AS's stock price is kr6.00. Initiator Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.379. Therefore, Initiator Pharma AS's PE Ratio (TTM) for today is At Loss.


Initiator Pharma AS EV-to-FCF Historical Data

The historical data trend for Initiator Pharma AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Initiator Pharma AS EV-to-FCF Chart

Initiator Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -10.38 -6.95 -5.76 -17.81 -19.54

Initiator Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.81 -16.16 -21.92 -23.10 -19.54

Competitive Comparison of Initiator Pharma AS's EV-to-FCF

For the Biotechnology subindustry, Initiator Pharma AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Initiator Pharma AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Initiator Pharma AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Initiator Pharma AS's EV-to-FCF falls into.


;
;

Initiator Pharma AS EV-to-FCF Calculation

Initiator Pharma AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=317.563/-18.288
=-17.36

Initiator Pharma AS's current Enterprise Value is kr317.56 Mil.
Initiator Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-18.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Initiator Pharma AS  (OSTO:INIT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Initiator Pharma AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.00/-0.379
=At Loss

Initiator Pharma AS's share price for today is kr6.00.
Initiator Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.379.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Initiator Pharma AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Initiator Pharma AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Initiator Pharma AS Business Description

Traded in Other Exchanges
N/A
Address
Co/ COBIS, Ole Maaloesvej 3, Copenhagen, DNK, 2200
Initiator Pharma AS is a research and development company engaged in the pharmaceutical development of drugs to be used for erectile dysfunction, depression, and pain. It Research is focused in the area of monoamine reuptake inhibitors.

Initiator Pharma AS Headlines

No Headlines